Methods, pharmaceutical and therapeutic compositions for administering adenosine

Abstract

The invention discloses methods for the chronic administration of adenosine, which contrary to the acute delivery of the drug by injection or infusion, acts in desensitizing adenosine receptors towards the action of adenosine. The methods and oral compositions of adenosine triphosphate (ATP), which is degraded to adenosine in vivo, can be used in the treatment of disorders and diseases that are therapeutically targeted by agonists or antagonists of adenosine receptors. One example is the stimulation of lipolysis in achieving weight loss in humans and in the treatment of obesity.

What is claimed is:  
     
         1 . A method for obtaining weight loss in humans by administering to a human suffering from overweight, an antagonist of adenosine A 1  receptor and at least one member selected from the group consisting of adenosine 5′-triphosphate and adenosine 5′-monophosphate.  
     
     
         2 . A method for maintaining weight reduction in humans by administering to a human in need of, an antagonist of adenosine A 1  receptor and at least one member selected from the group consisting of adenosine 5′-triphosphate and adenosine 5′-monphosphate.  
     
     
         3 . A method for preventing weight gain in humans by administering to a human in need of, an antagonist of adenosine A 1  receptor and at least one member from a group consisting of adenosine 5′-triphosphate and adenosine 5′-monophosphate.  
     
     
         4 . The method according to anyone of claims  1 - 3  wherein the amount of adenosine 5′-triphosphate or adenosine 5′-monophospate is about 0.1-100 milligrams/kg of body weight per 24 hours said administering is oral or sublingual.  
     
     
         5 . The method according to anyone of claims  1 - 3  wherein the amount of adenosine 5′-triphosphate or adenosine 5′-monophosphate is about 0.1-100 milligrams/kg of body weight per 24 hours and administering is topical.  
     
     
         6 . The method according to anyone of claims  1 - 3  wherein the amount of adenosine 5′-triphosphate or adenosine 5′-monophosphate is about 0.01-10 milligrams/kg of body weight per 24 hours and administering is by injection.  
     
     
         7 . The method according to anyone of claims  1 - 3  wherein the amount of the antagonist of adenosine A1 receptor is about 0.1-100 milligrams/kg of body weight per 24 hours and administering is oral or sublingual.  
     
     
         8 . The method according to anyone of claims  1 - 3  wherein the amount of the antagonist of the adenosine A1 receptor is about 0.1-100 milligrams/kg of body weight per 24 hours and administering is topical.  
     
     
         9 . The method according to anyone of claims  1 - 3  wherein the amount of the antagonist of the adenosine A1 receptor is about 0.01-10 milligrams/kg of body weight per 24 hours and administering is by injection.  
     
     
         10 . The method according to anyone of claims  1 - 3  wherein the antagonist of the adenosine A1 receptor comprises caffeine.  
     
     
         11 . The method according to anyone of claims  1 - 3  wherein the antagonist of the adenosine A1 receptor comprises theophylline.